Independence said its agreement with NantHealth involves a "very specific and complex lab study" related to certain types of cancer. The test will be covered for members with "specific conditions including rare cancers, tumors in children, metastatic cancer of unknown primary, primary brain cancer, triple negative breast cancer, and metastatic cancer where conventional therapies have been exhausted and patients remain candidates for further therapy. Coverage for the testing will be available to eligible members of Independence commercial plans in March 2016."